Herein, we developed PD1-overexpressing cancer cell membrane-derived NVs-coated Cur-loaded poly (lactic-co-polyglycolic acid) (PLGA) nanoparticles (PD1@Cur-PLGA) to integrate ICD and ICB therapy and enhance antitumor immune response (Figure 1A). Here, PDCD1 is linked to cancer.